Focusing on Indian economy, Indian companies, investment in Indian Capital, Bond and Commodity markets, Product innovations and launches by different companies throughout globe and their implications to economy, markets and future of the Company’s stakeholders, regulatory policy changes and changing political scenario of India and the World. Complies the India Story as it unfolds, to summarize a complete financial blog focusing on Growth of Indian Economy
Sunday, November 11, 2007
Biocon eyes US and Europe markets
India’s largest biotechnology company Biocon is planning to tap the potential of biosimilars in the regulated markets of the US and Europe, besides taking Insugen, its own version of insulin, to the global markets in a big way. The launch of biosimilars in the US and Europe is planned over the next 2 or 3 years, by which time proper laws would evolve for biosimilars in these regions. Biocon is in the process of registering with the regulatory authorities in the developed markets for the launch of Insugen. Insugen has already been licensed to a US market and to Bayer for China.
No comments:
Post a Comment